Cannon Global Investment Management LLC Buys Shares of 17,500 TScan Therapeutics, Inc. (NASDAQ:TCRX)

Cannon Global Investment Management LLC acquired a new stake in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 17,500 shares of the company’s stock, valued at approximately $139,000.

Separately, Pale Fire Capital SE boosted its stake in shares of TScan Therapeutics by 30.2% during the fourth quarter. Pale Fire Capital SE now owns 21,573 shares of the company’s stock valued at $126,000 after acquiring an additional 4,998 shares during the last quarter. 82.83% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on TCRX. BTIG Research began coverage on TScan Therapeutics in a research note on Thursday, May 16th. They issued a “buy” rating and a $12.00 price target on the stock. Wedbush reissued an “outperform” rating and issued a $10.00 price target on shares of TScan Therapeutics in a research note on Monday, May 13th. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of TScan Therapeutics in a research note on Tuesday, June 4th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $11.00 price target on shares of TScan Therapeutics in a research note on Monday, May 13th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $12.00.

TScan Therapeutics Stock Down 6.3 %

TCRX stock traded down $0.39 during midday trading on Friday, hitting $5.85. 6,045,997 shares of the company’s stock were exchanged, compared to its average volume of 277,667. The company has a current ratio of 5.23, a quick ratio of 5.23 and a debt-to-equity ratio of 0.19. TScan Therapeutics, Inc. has a 12-month low of $1.93 and a 12-month high of $9.69. The firm has a 50 day moving average price of $8.04 and a 200-day moving average price of $6.93. The stock has a market capitalization of $309.23 million, a price-to-earnings ratio of -4.57 and a beta of 0.93.

TScan Therapeutics (NASDAQ:TCRX) last issued its earnings results on Monday, May 13th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.07). The firm had revenue of $0.57 million during the quarter, compared to analyst estimates of $3.75 million. TScan Therapeutics had a negative return on equity of 61.13% and a negative net margin of 653.50%. On average, analysts anticipate that TScan Therapeutics, Inc. will post -1.25 EPS for the current year.

TScan Therapeutics Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.